Colorectal Cancer

William Grady, MD, highlights the convenience and compliance of blood-based tests compared to colonoscopy and stool-based tests for colorectal cancer screening.

William Grady, MD, talks about the latest research in colorectal cancer, including treatments targeting senescent cells that contribute to tumor formation.

If FIT results indicated colonoscopy, respondents preferred personal follow-up vs digital; significant barriers to undergoing fear of the test and positive cancer finding were the most significant barriers to follow-up.

Your daily dose of the clinical news you may have missed.

New data show up-to-date CRC screening rose from 20.8% in 2019 to 33.7% in 2023, with gains driven by stool testing and colonoscopy.

For initiating colorectal cancer screening in average-risk young adults, a default mailed outreach strategy outperformed 3 active choice options in a randomized study.

As the incidence of young-onset colorectal cancer continues to rise, the findings from a large Taiwanese population-based study support lowering the age for initial screening.

Your daily dose of the clinical news you may have missed.

Breakthrough device designation for the multicancer detection test is supported by clinical validation data demonstrating an overall specificity of 98.6% and sensitivity of 60%.

A new study of a circulating tumor DNA-based screening test revealed promising sensitivity and specificity for for CRC, but only 12.5% sensitivity for advanced neoplasia.

Only about 75% of people with a positive result on a stool-based test for colorectal cancer complete screening with a colonoscopy. Fendrick "won't rest" until it's 90%.

Mark Fendrick, MD, thinks that right now, the relative accuracy of blood-based tests for CRC compared with available alternatives is not quite comparable. He explains.

With a population goal of having 80% to 90% of age-eligible Americans screened for colorectal cancer, colonoscopy can not be the initial test for everyone, Fendrick emphasizes.

Never considered the carbon footprint left by a screening for colorectal cancer? Fendrick has and did the research to learn more. He explains in this short video.

GLP-1 receptor agonists showed promise in lowering obesity-related cancer risks in adults with type 2 diabetes, particularly colorectal cancer.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

The increase in stool-based CRC testing is a logical trend, Hendrick said in an interview, given the convenience plus the 2 million younger adults now eligible for screening.

DDW 2025. Follow-up colonoscopy after a positive stool-based test was superior among adults aged 45-49 and across diverse populations whose original test was mt-sDNA.

While smoking in the US continues to decline, the American Cancer Society reports mixed progress in major cancer risk factors, prevention, and screening.

GRAIL announced plans to present new support for the Galleri test's ability to simultaneously screen for multiple cancers plus its accuracy for cancer signal of origin prediction.

The increase in pancreatic cancer among Americans aged 15 to 34 is particularly alarming and should alert clinicians to heed relevant GI symptoms as suspicious.

The phone-based patient navigation intervention addressed barriers to CRC testing follow-up and included patient education.

Myths and fears about cancer screening may be keeping some of your patients from important tests. Always ask about misconceptions, and then offer the facts.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

The model identified BMI, tobacco use, and family history of CRC as the strongest predictors for advanced neoplasia in young adults.

Adding a deadline to a mailed invitation for FIT colorectal cancer screening resulted in improved return rates, according to new research.

New AGA guidelines conclude that it is not clear whether computer-aided detection systems for colonoscopy should be recommended for routine widespread use.

Cervical cancer screening rates remained below prepandemic levels, while rates for breast and colorectal cancers rebounded from pandemic declines.